Therapeutic Workshop Details
Cancer: The Odd Couple - Marrying Chemotherapy with Targeted Therapies
Thursday, October 11, 2007
8:15 AM
Twin Peaks North
There may be significant promise in cancer treatment by marrying traditional chemotherapeutic agents with newer, targeted therapies that interfere with cancer cell growth. This panel will discuss current issues in how to pick the best combinations and what we are seeing in the clinic with these new investigative regimens across cancers. Based on clinical data to date, is this cancer treatment strategy proving to be successful?
Moderators
- David R. Parkinson, M.D.; President and CEO, Nodality, Inc.
Panelists
- Daniel Adelman, MD; Senior Vice President, Research and Development, Sunesis
- Alan H. Auerbach; Chief Executive Officer; President and Founder, Cougar Biotechnology, Inc.
- Stephen A. Hill, B.M. B.Ch., M.A., F.R.C.S.; President and Chief Executive Officer, ArQul
- Steven R. Deitcher, MD; President & Chief Executive Officer, Hana Biosciences
Who's Who
David R. Parkinson, is President and CEO of Nodality Inc, South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making. Until recently Dr. Parkinson was senior vice president, Oncology Research and Development at Biogen Idec. Previously he had served as vice president, Oncology Development, at Amgen. At Biogen, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously, he held several senior oncology positions at Novartis. During his tenure at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. He had previously also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and then in Boston at New England Medical Center. Currently, Dr. Parkinson serves on the National Cancer Policy Forum of the Institute of Medicine. He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA?s Cody Medal. He currently is a member of the FDA?s Science Board. He was recently elected to the Board of Directors of the American Association of Cancer Research, and continues to serve as Chairman of the AACR Finance Committee.
Dr. Hill has served as ArQule's President and CEO since April 1999. Before joining ArQule, Dr. Hill was the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997-1999. Dr. Hill joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom. He held several senior positions there that included Medical Director, responsible for clinical trials of compounds across a broad range of therapeutic areas, including CNS, HIV, cardiovascular, metabolic and oncology products. Subsequently, he served as Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland, where he led the regulatory submissions for seven major new chemical entities. Dr. Hill also was a member of Roche's Portfolio Management, Research, Development and Pharmaceutical Division Executive Boards. Prior to Roche, Dr. Hill served seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery. Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University.
Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences in August 2007. Dr. Deitcher originally joined Hana as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Hana, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports.